Chemistry:6-MAPB

From HandWiki

6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) is an entactogen of the benzofuran family which is structurally related to 6-APB and MDMA.[1][2][3][4][5] It is known to be a serotonin releasing agent and, unlike MDMA, a potent serotonin 5-HT1B receptor agonist.[6] The drug is not known to have been widely sold as a "designer drug" but has been detected in analytical samples taken from individuals hospitalised after using drug combinations that included other benzofuran derivatives. 6-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014.[7][8] It was banned in the United Kingdom in June 2013, along with 9 other related compounds which were thought to produce similar effects.[9]

Interactions

See also

References

  1. ↑ "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy". J Psychopharmacol 35 (5): 512–536. May 2021. doi:10.1177/0269881120920420. PMID 32909493. 
  2. ↑ "Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques". Analytical and Bioanalytical Chemistry 407 (12): 3457–3470. May 2015. doi:10.1007/s00216-015-8552-2. PMID 25711990. https://researchonline.ljmu.ac.uk/id/eprint/3412/1/ABC-02336-2014.R1.pdf. 
  3. ↑ "New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems". Therapeutic Drug Monitoring 38 (1): 4–11. February 2016. doi:10.1097/FTD.0000000000000240. PMID 26327309. 
  4. ↑ "Neurochemical binding profiles of novel indole and benzofuran MDMA analogues". Naunyn-Schmiedeberg's Archives of Pharmacology 390 (1): 15–24. January 2017. doi:10.1007/s00210-016-1297-4. PMID 27650729. 
  5. ↑ "The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats". Psychopharmacology 237 (12): 3703–3714. December 2020. doi:10.1007/s00213-020-05648-z. PMID 32875347. 
  6. ↑ Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", US patent 20230150963, published 2023 May 18, assigned to Tactogen
  7. ↑ "New phenethylamines in Europe". Drug Test Anal 6 (7-8): 808–818. 2014. doi:10.1002/dta.1570. PMID 24574327. 
  8. ↑ EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA
  9. ↑ "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. https://www.gov.uk/government/publications/temporary-class-drug-order-report-on-benzofury-and-nbome-compounds.